CYP3A4 phenotyping with midazolam to predict sunitinib exposure.

2592 Background: Patients treated with sunitinib show high inter-patient variability in drug exposure (40-60%), which is largely unexplained. Since sunitinib is metabolized by CYP3A4, variability i...